Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia

Purpose. A phase III, randomized study was carried out to establish the most effective and safest treatment to improve the primary endpoints of cancer cachexia—lean body mass (LBM), resting energy expenditure (REE), and fatigue—and relevant secondary endpoints: appetite, quality of life, grip streng...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2010-02, Vol.15 (2), p.200-211
Hauptverfasser:	Mantovani, Giovanni, Macciò, Antonio, Madeddu, Clelia, Serpe, Roberto, Massa, Elena, Dessì, Mariele, Panzone, Filomena, Contu, Paolo
Format:	Artikel
Sprache:	eng
Schlagworte:	Appetite Stimulants - adverse effects Appetite Stimulants - therapeutic use Cachexia - drug therapy Cachexia - etiology Cachexia - metabolism Cancer cachexia Carnitine - adverse effects Carnitine - therapeutic use Combined approach Eicosapentaenoic Acid - adverse effects Eicosapentaenoic Acid - therapeutic use Fatigue Female Humans Interleukin-6 - metabolism Lean body mass Male Medroxyprogesterone - adverse effects Medroxyprogesterone - therapeutic use Megestrol Acetate - adverse effects Megestrol Acetate - therapeutic use Middle Aged Neoplasms - complications Neoplasms - metabolism Randomized phase III trial Resting energy expenditure Symptom Management and Supportive Care Thalidomide - adverse effects Thalidomide - therapeutic use Vitamin B Complex - adverse effects Vitamin B Complex - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!